Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

Key facts

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Principal Investigator

Yue He, M.D.

the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

Intervention

Sacituzumab Tirumotecan and Toripalimab(drug)

Enrollment

39 enrolled

Eligibility

18-75 years · All sexes

Timeline

2025 – 2028

Study locations (1)

• the Ninth People's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, Shanghai Municipality, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Squamous cell carcinoma of head and neck

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE3NCT07333274
  Compare Radiotherapy Plus Nimotuzumab Versus Radiotherapy Alone in Platinum-ineligible Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma
  Shandong Cancer Hospital and Institute
• RECRUITINGPHASE1NCT07182149
  A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
  Normunity AccelCo, Inc.
• RECRUITINGPHASE3NCT07026474
  Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC
  Universität des Saarlandes
• RECRUITINGNANCT07203911
  Surgeon-performed Ultrasound for Real-time Guidance In Oral Cancer Surgeries - A Multicenter Randomized Controlled Trial
  Tobias Todsen
• RECRUITINGNANCT07180901
  Proactive Risk-based Optimization & Notifications for Treatment & Outcomes in Head & Neck Cancer
  Centre hospitalier de l'Université de Montréal (CHUM)
• ACTIVE NOT RECRUITINGEARLY PHASE1NCT07435415
  Local Injection Methylene Blue Combined With Radiation in HNSCC Patients
  China Medical University Hospital
• RECRUITINGPHASE2NCT07040956
  A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.
  West China Hospital
• RECRUITINGPHASE2NCT06856213
  Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck.
  Grupo Español de Tratamiento de Tumores de Cabeza y Cuello

See all trials for Squamous cell carcinoma of head and neck →